The cyclooxygenase-2 selective inhibitor, etodolac, but not aspirin reduces neovascularization in a murine ischemic hind limb model

European Journal of Pharmacology

Volumn 627, Issue 1-3, 2010, Pages 223-228

  Tanaka, Kohei ^a   Yamamoto, Yasutaka ^a   Tsujimoto, Shunsuke ^a   Uozumi, Naonori ^b   Kita, Yoshihiro ^b   Yoshida, Akio ^a   Shimizu, Takao ^b   Hisatome, Ichiro ^a  

^a Division of Regenerative Medicine and Therapeutics   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cyclooxygenase; Neovascularization; Prostaglandin I2; Thromboxane A2

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ETODOLAC; PROSTACYCLIN; PROSTAGLANDIN E2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; INFLAMMATORY CELL; LEG ISCHEMIA; LIMB PERFUSION; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; VASCULAR ENDOTHELIUM;

ANIMALS; ASPIRIN; BONE MARROW CELLS; CELL TRANSPLANTATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; EICOSANOIDS; ETODOLAC; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GROUP IV PHOSPHOLIPASES A2; HINDLIMB; ISCHEMIA; LEUKOCYTES, MONONUCLEAR; MALE; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; REGIONAL BLOOD FLOW;

EID: 73449085771     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.058     Document Type: Article

References (32)

1. Amano H., Hayashi I., Endo H., Kitasato H., Yamashina S., Maruyama T., Kobayashi M., Sato K., Narita M., and Sugimoto Y. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 197 (2003) 221-232
2. Asahara T., Murohara T., Sullivan A., Silver M., van-der-Zee R., Li T., Witzenbichler B., Schatteman G., and Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
3. Ashton A.W., and Ware J.A. Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ. Res. 95 (2004) 372-379
4. Babaev V.R., Ding L., Reese J., Morrow J.D., Breyer M.D., Dey S.K., Fazio S., and Linton M.F. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 113 (2006) 108-117
5. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J., and VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343 (2000) 1520-1528
6. Burleigh M.E., Babaev V.R., Oates J.A., Harris R.C., Gautam S., Riendeau D., Marnett L.J., Morrow J.D., Fazio S., and Linton M.F. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105 (2002) 1816-1823
7. Chang S.H., Liu C.H., Conway R., Han D.K., Nithipatikom K., Trifan O.C., Lane T.F., and Hla T. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 591-596
8. Daniel T.O., Liu H., Morrow J.D., Crews B.C., and Marnett L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 59 (1999) 4574-4577
9. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van-De-Putte L.B., and Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 12 (1998) 1063-1073
10. Egan K.M., Wang M., Fries S., Lucitt M.B., Zukas A.M., Puré E., Lawson J.A., and FitzGerald G.A. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111 (2005) 334-342
11. Fitzgerald G.A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351 (2004) 1709-1711
12. Futagami A., Ishizaki M., Fukuda Y., Kawana S., and Yamanaka N. Wound healing involves induction of cyclooxygenase-2 expression in rat skin. Lab. Invest. 82 (2002) 1503-1513
13. Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., Shoor S., and Ray W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
14. Ishizaki T., Katsumata K., Tsuchida A., Wada T., Mori Y., Hisada M., Kawakita H., and Aoki T. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int. J. Mol. Med. 17 (2006) 357-362
15. Kamihata H., Matsubara H., Nishiue T., Fujiyama S., Tsutsumi Y., Ozono R., Masaki H., Mori Y., Iba O., Tateishi E., Kosaki A., Shintani S., Murohara T., Imaizumi T., and Iwasaka T. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 104 (2001) 1046-1052
16. Kuwano T., Nakao S., Yamamoto H., Tsuneyoshi M., Yamamoto T., Kuwano M., and Ono M. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J. 18 (2004) 300-310
17. Matoba S., Tatsumi T., Murohara T., Imaizumi T., Katsuda Y., Ito M., Saito Y., Uemura S., Suzuki H., Fukumoto S., Yamamoto Y., Onodera R., Teramukai S., Fukushima M., and Matsubara H. TACT Follow-up Study Investigators. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am. Heart J. 156 (2008) 1010-1018
18. Michel F., Silvestre J.S., Waeckel L., Corda S., Verbeuren T., Vilaine J.P., Clergue M., Duriez M., and Levy B.I. Thromboxane A2/prostaglandin H2 receptor activation mediates angiotensin II-induced postischemic neovascularization. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 488-493
19. Mitchell J.A., Lucas R., Vojnovic I., Hasan K., Pepper J.R., and Warner T.D. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J. 20 (2006) 2468-2475
20. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
21. Okamoto A., Shirakawa T., Bito T., Shigemura K., Hamada K., Gotoh A., Fujisawa M., and Kawabata M. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology 71 (2008) 156-160
22. Otsuka H., Akashi H., Murohara T., Okazaki T., Shintani S., Tayama K., Sasaki K., Imaizumi T., and Aoyagi S. The prostacyclin analog beraprost sodium augments the efficacy of therapeutic angiogenesis induced by autologous bone marrow cells. Ann. Vasc. Surg. 20 (2006) 646-652
23. Rivard A., Fabre J.E., Silver M., Chen D., Murohara T., Kearney M., Magner M., Asahara T., and Isner J.M. Age-dependent impairment of angiogenesis. Circulation 99 (1999) 111-120
24. Schulz C., Konrad I., Sauer S., Orschiedt L., Koellnberger M., Lorenz R., Walter U., and Massberg S. Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. Thromb. Haemost. 99 (2008) 190-195
25. Shtivelband M.I., Juneja H.S., Lee S., and Wu K.K. Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression. J. Thromb. Haemost. 1 (2003) 2225-2233
26. Sugihara S., Yamamoto Y., Matsuura T., Narazaki G., Yamasaki A., Igawa G., Matsubara K., Miake J., Igawa O., Shigemasa C., and Hisatome I. Age-related BM-MNC dysfunction hampers neovascularization. Mech. Ageing Dev. 128 (2007) 511-516
27. Tateishi-Yuyama E., Matsubara H., Murohara T., Ikeda U., Shintani S., Masaki H., Amano K., Kishimoto Y., Yoshimoto K., Akashi H., Shimada K., Iwasaka T., and Imaizumi T. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360 (2002) 427-435
28. Tateno K., Minamino T., Toko H., Akazawa H., Shimizu N., Takeda S., Kunieda T., Miyauchi H., Oyama T., Matsuura K., Nishi J., Kobayashi Y., Nagai T., Kuwabara Y., Iwakura Y., Nomura F., Saito Y., and Komuro I. Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ. Res. 98 (2006) 1194-1202
29. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. Natl. Cancer Inst. 94 (2002) 252-266
30. Uozumi N., Kume K., Nagase T., Nakatani N., Ishii S., Tashiro F., Komagata Y., Maki K., Ikuta K., Ouchi Y., Miyazaki J., and Shimizu T. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 390 (1997) 618-622
31. Wang D., and DuBois R.N. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 415-416
32. Williams C.S., Tsujii M., Reese J., Dey S.K., and DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105 (2002) 1589-1594